Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement

Core Insights - Royalty Pharma and Ascendis Pharma have entered into a $150 million capped synthetic royalty funding agreement based on U.S. net sales of Yorvipath, the first FDA-approved treatment for hypoparathyroidism in adults [1][2] Group 1: Agreement Details - Ascendis Pharma will receive an upfront payment of $150 million in exchange for a 3% royalty on U.S. net sales of Yorvipath [2] - Royalty payments to Royalty Pharma will cease upon reaching a multiple of 2.0x, or 1.65x if royalties are received by December 31, 2029 [2] Group 2: Company Profiles - Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation in the biopharmaceutical industry, with a portfolio that includes royalties on over 35 commercial products [4] - Ascendis Pharma focuses on developing new therapies using its innovative TransCon technology platform, aiming to make a meaningful difference in patients' lives [5]